Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.
Identifieur interne : 002338 ( PubMed/Corpus ); précédent : 002337; suivant : 002339Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.
Auteurs : G M Leung ; W W Lim ; L-M Ho ; T-H Lam ; A C Ghani ; C A Donnelly ; C. Fraser ; S. Riley ; N M Ferguson ; R M Anderson ; A J HedleySource :
- Epidemiology and infection [ 0950-2688 ] ; 2006.
English descriptors
- KwdEn :
- MESH :
- chemical , analysis : Immunoglobulin G.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- Antibody Formation, Blood Donors, Geography, Health Personnel, Humans, Seroepidemiologic Studies.
Abstract
We systematically reviewed the current understanding of human population immunity against SARS-CoV in different groups, settings and geography. Our meta-analysis, which included all identified studies except those on wild animal handlers, yielded an overall seroprevalence of 0.10% [95% confidence interval (CI) 0.02-0.18]. Health-care workers and others who had close contact with SARS patients had a slightly higher degree of seroconversion (0.23%, 95% CI 0.02-0.45) compared to healthy blood donors, others from the general community or non-SARS patients recruited from the health-care setting (0.16%, 95% CI 0-0.37). When analysed by the two broad classes of testing procedures, it is clear that serial confirmatory test protocols resulted in a much lower estimate (0.050%, 95% CI 0-0.15) than single test protocols (0.20%, 95% CI 0.06-0.34). Potential epidemiological and laboratory pitfalls are also discussed as they may give rise to false or inconsistent results in measuring the seroprevalence of IgG antibodies to SARS-CoV.
DOI: 10.1017/S0950268805004826
PubMed: 16490123
Links to Exploration step
pubmed:16490123Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.</title><author><name sortKey="Leung, G M" sort="Leung, G M" uniqKey="Leung G" first="G M" last="Leung">G M Leung</name><affiliation><nlm:affiliation>Department of Community Medicine, University of Hong Kong, Pokfulam, Hong Kong, ChinaTakemi Program, Harvard School of Public Health, Boston, MA, USA. gmleung@hkucc.hk</nlm:affiliation></affiliation></author><author><name sortKey="Lim, W W" sort="Lim, W W" uniqKey="Lim W" first="W W" last="Lim">W W Lim</name></author><author><name sortKey="Ho, L M" sort="Ho, L M" uniqKey="Ho L" first="L-M" last="Ho">L-M Ho</name></author><author><name sortKey="Lam, T H" sort="Lam, T H" uniqKey="Lam T" first="T-H" last="Lam">T-H Lam</name></author><author><name sortKey="Ghani, A C" sort="Ghani, A C" uniqKey="Ghani A" first="A C" last="Ghani">A C Ghani</name></author><author><name sortKey="Donnelly, C A" sort="Donnelly, C A" uniqKey="Donnelly C" first="C A" last="Donnelly">C A Donnelly</name></author><author><name sortKey="Fraser, C" sort="Fraser, C" uniqKey="Fraser C" first="C" last="Fraser">C. Fraser</name></author><author><name sortKey="Riley, S" sort="Riley, S" uniqKey="Riley S" first="S" last="Riley">S. Riley</name></author><author><name sortKey="Ferguson, N M" sort="Ferguson, N M" uniqKey="Ferguson N" first="N M" last="Ferguson">N M Ferguson</name></author><author><name sortKey="Anderson, R M" sort="Anderson, R M" uniqKey="Anderson R" first="R M" last="Anderson">R M Anderson</name></author><author><name sortKey="Hedley, A J" sort="Hedley, A J" uniqKey="Hedley A" first="A J" last="Hedley">A J Hedley</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16490123</idno><idno type="pmid">16490123</idno><idno type="doi">10.1017/S0950268805004826</idno><idno type="wicri:Area/PubMed/Corpus">002338</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002338</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.</title><author><name sortKey="Leung, G M" sort="Leung, G M" uniqKey="Leung G" first="G M" last="Leung">G M Leung</name><affiliation><nlm:affiliation>Department of Community Medicine, University of Hong Kong, Pokfulam, Hong Kong, ChinaTakemi Program, Harvard School of Public Health, Boston, MA, USA. gmleung@hkucc.hk</nlm:affiliation></affiliation></author><author><name sortKey="Lim, W W" sort="Lim, W W" uniqKey="Lim W" first="W W" last="Lim">W W Lim</name></author><author><name sortKey="Ho, L M" sort="Ho, L M" uniqKey="Ho L" first="L-M" last="Ho">L-M Ho</name></author><author><name sortKey="Lam, T H" sort="Lam, T H" uniqKey="Lam T" first="T-H" last="Lam">T-H Lam</name></author><author><name sortKey="Ghani, A C" sort="Ghani, A C" uniqKey="Ghani A" first="A C" last="Ghani">A C Ghani</name></author><author><name sortKey="Donnelly, C A" sort="Donnelly, C A" uniqKey="Donnelly C" first="C A" last="Donnelly">C A Donnelly</name></author><author><name sortKey="Fraser, C" sort="Fraser, C" uniqKey="Fraser C" first="C" last="Fraser">C. Fraser</name></author><author><name sortKey="Riley, S" sort="Riley, S" uniqKey="Riley S" first="S" last="Riley">S. Riley</name></author><author><name sortKey="Ferguson, N M" sort="Ferguson, N M" uniqKey="Ferguson N" first="N M" last="Ferguson">N M Ferguson</name></author><author><name sortKey="Anderson, R M" sort="Anderson, R M" uniqKey="Anderson R" first="R M" last="Anderson">R M Anderson</name></author><author><name sortKey="Hedley, A J" sort="Hedley, A J" uniqKey="Hedley A" first="A J" last="Hedley">A J Hedley</name></author></analytic><series><title level="j">Epidemiology and infection</title><idno type="ISSN">0950-2688</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody Formation</term><term>Blood Donors</term><term>Geography</term><term>Health Personnel</term><term>Humans</term><term>Immunoglobulin G (analysis)</term><term>SARS Virus (immunology)</term><term>SARS Virus (pathogenicity)</term><term>Seroepidemiologic Studies</term><term>Severe Acute Respiratory Syndrome (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Antibody Formation</term><term>Blood Donors</term><term>Geography</term><term>Health Personnel</term><term>Humans</term><term>Seroepidemiologic Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We systematically reviewed the current understanding of human population immunity against SARS-CoV in different groups, settings and geography. Our meta-analysis, which included all identified studies except those on wild animal handlers, yielded an overall seroprevalence of 0.10% [95% confidence interval (CI) 0.02-0.18]. Health-care workers and others who had close contact with SARS patients had a slightly higher degree of seroconversion (0.23%, 95% CI 0.02-0.45) compared to healthy blood donors, others from the general community or non-SARS patients recruited from the health-care setting (0.16%, 95% CI 0-0.37). When analysed by the two broad classes of testing procedures, it is clear that serial confirmatory test protocols resulted in a much lower estimate (0.050%, 95% CI 0-0.15) than single test protocols (0.20%, 95% CI 0.06-0.34). Potential epidemiological and laboratory pitfalls are also discussed as they may give rise to false or inconsistent results in measuring the seroprevalence of IgG antibodies to SARS-CoV.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16490123</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0950-2688</ISSN><JournalIssue CitedMedium="Print"><Volume>134</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Epidemiology and infection</Title><ISOAbbreviation>Epidemiol. Infect.</ISOAbbreviation></Journal><ArticleTitle>Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.</ArticleTitle><Pagination><MedlinePgn>211-21</MedlinePgn></Pagination><Abstract><AbstractText>We systematically reviewed the current understanding of human population immunity against SARS-CoV in different groups, settings and geography. Our meta-analysis, which included all identified studies except those on wild animal handlers, yielded an overall seroprevalence of 0.10% [95% confidence interval (CI) 0.02-0.18]. Health-care workers and others who had close contact with SARS patients had a slightly higher degree of seroconversion (0.23%, 95% CI 0.02-0.45) compared to healthy blood donors, others from the general community or non-SARS patients recruited from the health-care setting (0.16%, 95% CI 0-0.37). When analysed by the two broad classes of testing procedures, it is clear that serial confirmatory test protocols resulted in a much lower estimate (0.050%, 95% CI 0-0.15) than single test protocols (0.20%, 95% CI 0.06-0.34). Potential epidemiological and laboratory pitfalls are also discussed as they may give rise to false or inconsistent results in measuring the seroprevalence of IgG antibodies to SARS-CoV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>G M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Community Medicine, University of Hong Kong, Pokfulam, Hong Kong, ChinaTakemi Program, Harvard School of Public Health, Boston, MA, USA. gmleung@hkucc.hk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>W W</ForeName><Initials>WW</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>L-M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>T-H</ForeName><Initials>TH</Initials></Author><Author ValidYN="Y"><LastName>Ghani</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Donnelly</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Riley</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>N M</ForeName><Initials>NM</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Hedley</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Epidemiol Infect</MedlineTA><NlmUniqueID>8703737</NlmUniqueID><ISSNLinking>0950-2688</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001782" MajorTopicYN="N">Blood Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005843" MajorTopicYN="N">Geography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16490123</ArticleId><ArticleId IdType="pii">S0950268805004826</ArticleId><ArticleId IdType="doi">10.1017/S0950268805004826</ArticleId><ArticleId IdType="pmc">PMC2870380</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2004 Dec;42(12):5885-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15583332</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1377-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12775826</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Jun 20;300(5627):1961-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12766206</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Jun 20;300(5627):1966-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12766207</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Jan;79(2):884-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15613317</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2005 Mar;75(3):463-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15648061</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2005 Mar;75(3):455-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15648064</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2003 May 1;187(9):1404-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12717621</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Jul 31;349(5):508-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12890855</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 17;361(9370):1701-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12767737</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2003 Sep;9(9):1037-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14519236</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Yi Jun Yi Da Xue Xue Bao. 2003 Oct;23(10):1085-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14559701</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2003 Oct 17;52(41):986-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14561956</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Oct 25;362(9393):1353-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14585636</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2003 Oct;26(10):583-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14633437</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2003 Nov;9(11):1453-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14718090</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Feb 15;189(4):642-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14767817</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2542-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14983045</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):176-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15030679</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):249-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15030691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Mar 13;363(9412):841-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15031027</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2004 Apr;10(4):368-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15034574</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Yu Fang Yi Xue Za Zhi. 2004 Mar;38(2):81-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15061910</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Apr 22;350(17):1731-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15102999</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2004 May;42(5):2306-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15131220</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2004 May;42(5):2351-2</Citation><ArticleIdList><ArticleId IdType="pubmed">15131233</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2004 Mar;27(3):151-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15130323</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Genet. 2003 Sep 12;4:9</Citation><ArticleIdList><ArticleId IdType="pubmed">12969506</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 May 29;363(9423):1825; author reply 1826-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15172784</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 May 29;363(9423):1825; author reply 1826-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15172785</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 May 29;363(9423):1825-6; author reply 1826-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15172786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 May 29;363(9423):1826; author reply 1826-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15172787</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2004 Jun;42(6):2629-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15184444</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Infect Dis. 2004;36(4):287-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15198186</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Sep;10(9):1653-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15498170</ArticleId></ArticleIdList></Reference><Reference><Citation>Control Clin Trials. 1986 Sep;7(3):177-88</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Invest. 1994 Aug;23(4-5):313-21</Citation><ArticleIdList><ArticleId IdType="pubmed">7959963</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 1998;16:593-617</Citation><ArticleIdList><ArticleId IdType="pubmed">9597143</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002338 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002338 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16490123
|texte= Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16490123" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |